What is Convergent Therapeutics worth?
$280.0Mlast known valuation
Convergent Therapeutics last raised $22.2M in its Early Stage VC (Jul 2024).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Convergent Therapeutics
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jul 2024 | Early Stage VC | $22.2M | ▮ | ▮ |
| May 2023 | Early Stage VC (Series A) | $90.0M | ▮ | ▮ |
How Convergent Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Convergent Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is Convergent Therapeutics worth?
- Convergent Therapeutics's last known valuation is $280.0M.
- How much has Convergent Therapeutics raised?
- Convergent Therapeutics has raised $130.0M in total funding across 2 recorded rounds.
- When did Convergent Therapeutics last raise?
- Convergent Therapeutics last raised in Jul 2024 (Early Stage VC), raising $22.2M.